Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.95)
# 1,387
Out of 5,149 analysts
10
Total ratings
83.33%
Success rate
47.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Initiates: Buy | $14 | $4.67 | +199.79% | 1 | Mar 2, 2026 | |
| EXEL Exelixis | Upgrades: Outperform | $48 | $40.74 | +17.82% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $23.33 | -14.27% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $2.97 | +203.03% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $2.58 | +287.60% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $9.85 | +82.74% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $34.31 | -21.31% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $100.22 | -58.09% | 1 | Aug 8, 2023 |
Relmada Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $14
Current: $4.67
Upside: +199.79%
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $40.74
Upside: +17.82%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $23.33
Upside: -14.27%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $2.97
Upside: +203.03%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $2.58
Upside: +287.60%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $9.85
Upside: +82.74%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $34.31
Upside: -21.31%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $100.22
Upside: -58.09%